about
Taxanes as a risk factor for acute adverse reactions to iodinated contrast media in cancer patientsPalbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients?Paraneoplastic hypocalcemia-induced heart failure in advanced breast cancer: A case report and literature review.Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.Glutathione, glutathione disulfide, and S-glutathionylated proteins in cell cultures.Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.Differences in biological features of breast cancer between Caucasian (Italian) and African (Tanzanian) populations.Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.Biology matters: the clinical impact of single-receptor discordance on breast cancer.Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)Increased frequency of acute reactions to iodinated contrast media in cancer patients treated with anti-CTLA-4 immunomodulatory antibodiesThe impact of radiotherapy, trastuzumab and hormonal therapy on cardiac fibrosis. More is worse?Plasma Androgen Receptor in Prostate CancerThe Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment
P50
Q34005121-B5A708DC-11EC-428A-9003-F53DE90077F7Q34394399-088022DB-679A-4F06-B3F9-B0B525AFED07Q35384490-5612B9FA-C357-412E-B86C-5601DB7CA46BQ35871419-9D72D96A-2029-4DB0-BBAF-0348605ABFCCQ38573858-06504429-5E40-4840-A34E-A5057340F61BQ40421385-C033D3F6-3EF7-484F-A7F7-074345C8FBA5Q41553118-7408E47F-3710-4EBD-98D5-3AB4D947DE84Q41716164-5F827D5D-6A86-4DE3-B27B-955F685E822AQ43521216-E15F59B4-670F-4120-BD50-635F1B5B803EQ43935327-03D3A170-EFD1-4E07-A599-2A2D8FAB0748Q46134374-069CC382-1A14-40AB-8192-7CC0C2EDB029Q54449084-8AE7D148-C8D4-42B9-9CF6-3BFF86A99C60Q56358229-D3EBD60C-2AED-4716-8B5B-74ECD7897B4DQ56876578-EAEEB7D3-8527-4F8F-BA68-F3C876746EB3Q87855621-51ACE23F-1BB3-4D22-8C1A-2D99CAF6178DQ91125795-63CB2121-3A11-4719-8295-BBE0408E279EQ91809322-0D0FC098-A695-4F74-B4B0-842A8EAD8508
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
A Farolfi
@ast
A Farolfi
@en
A Farolfi
@es
A Farolfi
@nl
A Farolfi
@sl
type
label
A Farolfi
@ast
A Farolfi
@en
A Farolfi
@es
A Farolfi
@nl
A Farolfi
@sl
prefLabel
A Farolfi
@ast
A Farolfi
@en
A Farolfi
@es
A Farolfi
@nl
A Farolfi
@sl
P106
P1153
55048024800
P31
P496
0000-0002-3289-8041